Bioidentical Hormones: What they are, what they can do, and what they can't

What the evidence really shows

Evidence for hormone therapy during menopause comes largely from studies conducted with oral synthetic hormones. This is an important limitation: many of the positive claims about bioidentical hormones versus synthetic ones are based on observational studies, not on randomized controlled trials with direct comparisons.

What is well-supported:

• Transdermal estradiol bypasses liver metabolism (first-pass effect) and is therefore not associated with an increased risk of thrombosis, unlike orally administered estrogen. This is confirmed by the German S3 guideline on peri- and postmenopause (AWMF 015-062, 2020).
• Micronized progesterone has a sedative effect via GABA-A receptors and can improve sleep quality, which synthetic progestogens do not do to the same extent.
• Bioidentical progesterone has a more favorable receptor profile than older synthetic progestogens such as medroxyprogesterone acetate (MPA), which showed an increase in breast cancer in the 2002 Women's Health Initiative (WHI) and contributed to the poor reputation of HRT.

What is not yet sufficiently proven:

The claim that bioidentical hormones are fundamentally safer than synthetic ones is incorrect. There are indications of a more favorable profile for specific active ingredients (micronized progesterone vs. MPA), but there are no sufficient direct comparative RCTs. The German Menopause Society therefore recommends approved finished medicinal products containing bioidentical active ingredients, rather than the uncritical assertion that bioidentical is better per se.

You can read about how to recognize if you might be lacking progesterone in your cycle, and why a single value says little, in the article on Recognizing progesterone deficiency.

Compounded hormones: The problem with individualized formulations:

Saliva-test-based hormone levels, individual compounding recipes, and the idea of a perfectly matched hormone cocktail sound tempting. The problem is the lack of standardization. The amount of active ingredient in compounded preparations is difficult to reproduce, quality controls are not mandatory, and there are no clinical trials for approval. The AWMF, the International Menopause Society (IMS), and ACOG expressly advise against them. Those who want bioidentical hormones can get them in a standardized, safe form through approved finished medicinal products.

For whom is HRT useful?

The S3 guideline of the AWMF (2020, update under revision) recommends hormone therapy if vasomotor symptoms such as hot flashes and night sweats, sleep disturbances, urogenital symptoms, or a significant reduction in quality of life are present. There is no longer a rigid age limit.

When the decision should be individually weighed:

• Women with an increased risk of breast cancer (family history, BRCA mutation) or a history need specialized medical advice.
• Women with active or recently treated hormone receptor-positive breast cancer: HRT is generally contraindicated.
• Women with a history of thrombosis: transdermal estradiol is favorable regarding the risk of thrombosis, but the overall picture must be medically evaluated.
• Early perimenopause (40 to 45 years): Here, an early start can have a more favorable long-term effect on cardiovascular risk and bone health.

Non-hormonal alternatives: What if HRT is not an option?

For women for whom hormone therapy is contraindicated or who refuse it, there are several alternatives with varying degrees of evidence:

• Fezolinetant (Veoza): an NK3 receptor antagonist that specifically inhibits the neurokinin B signaling pathway responsible for hot flashes. Approved in Germany since 2024, well-tolerated in studies to date.
• Phytoestrogensfrom soy (isoflavones), as contained in Hormonic Midlife Formula: show moderate effects on hot flashes in some studies, especially in women who produce equol. Not an alternative to HRT for severe symptoms.
• Herbal medicines such as Cimicifuga racemosa (black cohosh): In the Cochrane review, a tendency towards effectiveness, no significance. "Can" recommendation in the guidelines.
• Specific dietary supplements such as saffron or creatine, which can support different menopausal symptoms. Here, a combination preparation like the Midlife Bundlecan make sense, as it supports you holistically,
• SSRIs and SNRIs (Venlafaxine, Paroxetine): off-label for vasomotor symptoms, act via serotonergic and noradrenergic pathways. Paroxetine is approved in the USA for this indication.

A more detailed classification of non-hormonal options and the influence of nutrition on menopausal symptoms can be found in our nutrition article on menopause and in the hot flashes guide.

Key takeaways

• Bioidentical hormones means: chemically identical to the body's own hormones. The term is not protected and is used for very different products.
• Approved bioidentical finished medicinal products (Estrogel, Utrogest) are the gold standard of modern menopausal medicine and recommended by guidelines.
• Compounded, individually prepared bioidentical hormones are not standardized and not recommended by professional societies.
• Transdermal estradiol and micronized progesterone show a more favorable risk profile in observational studies than older oral synthetic combinations.
• The decision for or against HRT is always individual and requires medical supervision.